Home › Research › Biomarkers
Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage
Meeker KL, Butt OH, Gordon BA, Fagan AM, Schindler SE, Morris JC, Benzinger TLS, Ances BM.. Neurobiology of disease, 2022-02-12
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Cerebrospinal fluid (CSF) neurofilament light chain (NfL) reflects neuro-axonal damage and is increasingly used to evaluate disease progression across neurological conditions including Alzheimer disease (AD). However, it is unknown how NfL relates to specific types of brain tissue. We sought to determine whether CSF NfL is more strongly associated with total gray matter, white matter, or white matter hyperintensity (WMH) volume, and to quantify the relative importance of brain tissue volume, age, and AD marker status (i.e., APOE genotype, brain amyloidosis, tauopathy, and cognitive status) in predicting CSF NfL. Methods 419 participants (Clinical Dementia Rating [CDR] Scale > 0, N = 71) had CSF, magnetic resonance imaging (MRI), and neuropsychological data. A subset had amyloid positron emission tomography (PET) and tau PET. Pearson correlation analysis was used to determine the association between CSF NfL and age. Multiple regression was used to determine which brain volume (i.e., gray, white, or WMH volume) most strongly associated with CSF NfL. Stepwise regression and dominance analyses were used to determine the individual contributions and relative importance of brain volume, age, and AD marker status in predicting CSF NfL. Results CSF NfL increased with age (r = 0.59, p 0.05) when considered simultaneously. Age and WMH volume were consistently more important (i.e., have greater R 2 values) than AD markers when predicting CSF NfL. Conclusions CSF NfL is a non-specific marker of aging and white matter integrity with limited sensitivity to specific markers of AD. CSF NfL likely reflects processes associated with cerebrovascular disease.
What this study adds
Evidence grade: Low
The record lists 71 participants. In 419 participants, cerebrospinal fluid neurofilament light chain increased with age and was more strongly related to white matter hyperintensity volume and age than to Alzheimer marker status. This concerns a marker of aging and white matter damage, not a treatment, cure or prevention of Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Meeker, K. L., Butt, O. H., Gordon, B. A., Fagan, A. M., Schindler, S. E., Morris, J. C., et al. (2022). Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2022.105662
Vancouver
Meeker KL, Butt OH, Gordon BA, Fagan AM, Schindler SE, Morris JC, et al. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of disease. 2022. doi:10.1016/j.nbd.2022.105662. PMID: 35167933.
BibTeX
@article{meeker2022-35167933,
author = {Meeker, K. L. and Butt, O. H. and Gordon, B. A. and Fagan, A. M. and Schindler, S. E. and Morris, J. C. and Benzinger, T. L. S. and Ances, B. M.},
title = {{Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage}},
journal = {Neurobiology of disease},
year = {2022},
doi = {10.1016/j.nbd.2022.105662},
pmid = {35167933},
url = {https://doi.org/10.1016/j.nbd.2022.105662}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We sought to determine whether CSF NfL is more strongly associated with total gray matter, white matter, or white matter hyperintensity (WMH) volume, and to quantify the relative importance of brain tissue volume, age, and AD marker status (i.e., APOE genotype, brain amyloidosis, tauopathy, and cognitive status) in predicting CSF NfL.
- Multiple regression was used to determine which brain volume (i.e., gray, white, or WMH volume) most strongly associated with CSF NfL.
- Results CSF NfL increased with age (r = 0.59, p 0.05) when considered simultaneously.
- CSF NfL likely reflects processes associated with cerebrovascular disease.
Why it matters
In 419 participants, cerebrospinal fluid neurofilament light chain increased with age and was more strongly related to white matter hyperintensity volume and age than to Alzheimer marker status. This concerns a marker of aging and white matter damage, not a treatment, cure or prevention of Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants71
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of disease) |
| Journal's citation record | 2 / 4 | Neurobiology of Disease: journal h-index 225 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 71 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 57 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 7.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 38 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Beau M. Ances: h-index 81 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35167933) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.